Literature DB >> 16373397

A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin.

Jiwen Li1, Junjiang Fu, Charalambos Toumazou, Ho-Geun Yoon, Jiemin Wong.   

Abstract

The N-terminal domain of AR is known to engage a hormone-dependent interaction with its C-terminal ligand-binding domain, and this N/C interaction is known to modulate AR transcriptional activity. Using Xenopus oocytes as a model system to study transcriptional regulation in chromatin, we found that two previously reported N/C interaction-defective AR mutants, one with deletion of 23FQNLF27(ARDeltaF) and one with a Gly 21 to Glu mutation (ARG21E), were surprisingly inactive in activating transcription from various reporters assembled into chromatin. Further study using chromatin immunoprecipitation assay revealed that these mutants failed to bind both mouse mammary tumor virus-long terminal repeat and prostate-specific antigen enhancer assembled into chromatin. This defect is specific to chromatin because both mutants could bind to a consensus AR response element in vitro and activate transcription driven by mouse mammary tumor virus-long terminal repeat in transient transfection as effective as the wild-type AR. To further substantiate this novel finding, we established 293 cell lines that stably expressed either AR or ARDeltaF mutant in an inducible manner. Using these cell lines, we confirmed by using chromatin immunoprecipitation assay that AR but not ARDeltaF could bind to the endogenous prostate-specific antigen enhancer. Furthermore, we found that the ARDeltaF mutant interacts poorly with Brg1, the ATPase subunit of the chromatin-remodeling factor SWI/SNF. Taken together, our study reveals a novel role of AR N/C interaction in control of AR chromatin binding and suggests a working model that the proper N/C interaction is required for AR to recruit SWI/SNF complex, which in turn remodels chromatin to allow AR to bind to AR response elements in chromatin.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16373397     DOI: 10.1210/me.2005-0298

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  34 in total

1.  The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Authors:  Hongbo Wang; Ming Jiang; Hongmei Cui; Mengqian Chen; Ralph Buttyan; Simon W Hayward; Tsonwin Hai; Zhengxin Wang; Chunhong Yan
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

2.  Androgen receptor serine 81 phosphorylation mediates chromatin binding and transcriptional activation.

Authors:  Shaoyong Chen; Sarah Gulla; Changmeng Cai; Steven P Balk
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

3.  Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity.

Authors:  Junjiang Fu; Jun Jiang; Jiwen Li; Shanshan Wang; Guang Shi; Qin Feng; Eileen White; Jun Qin; Jiemin Wong
Journal:  J Biol Chem       Date:  2009-01-05       Impact factor: 5.157

Review 4.  Chromatin remodeling during glucocorticoid receptor regulated transactivation.

Authors:  Heather A King; Kevin W Trotter; Trevor K Archer
Journal:  Biochim Biophys Acta       Date:  2012-03-06

5.  Identification of SRC3/AIB1 as a preferred coactivator for hormone-activated androgen receptor.

Authors:  X Edward Zhou; Kelly M Suino-Powell; Jun Li; Yuanzheng He; Jeffrey P Mackeigan; Karsten Melcher; Eu-Leong Yong; H Eric Xu
Journal:  J Biol Chem       Date:  2010-01-19       Impact factor: 5.157

Review 6.  Chromosome Y genetic variants: impact in animal models and on human disease.

Authors:  J W Prokop; C F Deschepper
Journal:  Physiol Genomics       Date:  2015-08-18       Impact factor: 3.107

7.  A novel androgen receptor amino terminal region reveals two classes of amino/carboxyl interaction-deficient variants with divergent capacity to activate responsive sites in chromatin.

Authors:  Eleanor F Need; Howard I Scher; Amelia A Peters; Nicole L Moore; Albert Cheong; Charles J Ryan; Gary A Wittert; Villis R Marshall; Wayne D Tilley; Grant Buchanan
Journal:  Endocrinology       Date:  2009-03-12       Impact factor: 4.736

8.  ARF represses androgen receptor transactivation in prostate cancer.

Authors:  Wenfu Lu; Yingqiu Xie; Yufang Ma; Robert J Matusik; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2013-02-28

9.  Peroxisome proliferator-activated receptor gamma coactivator-1alpha interacts with the androgen receptor (AR) and promotes prostate cancer cell growth by activating the AR.

Authors:  Masaki Shiota; Akira Yokomizo; Yasuhiro Tada; Junichi Inokuchi; Katsunori Tatsugami; Kentaro Kuroiwa; Takeshi Uchiumi; Naohiro Fujimoto; Narihito Seki; Seiji Naito
Journal:  Mol Endocrinol       Date:  2009-11-02

10.  Cyclin D1 repressor domain mediates proliferation and survival in prostate cancer.

Authors:  M J Schiewer; L M Morey; C J Burd; Y Liu; D E Merry; S-M Ho; K E Knudsen
Journal:  Oncogene       Date:  2008-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.